All studies
Endocrinology · EHR · England

Ryan 2026

Type 2 diabetes

DAG reportedQBA performedITTSuperiorityAcademia4/5 disclosures
Comparisons
2
In the analysis
0
2 withheld
Target trials
1
Emulations reported
2
2 treatments

Comparisons

2 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
All-cause mortality
vs EMPA-REG OUTCOME·HR·Efficacy
0.680.57–0.82
0.760.69–0.83
not pooledMajor deviation
All-cause mortality
vs EMPA-REG OUTCOME·HR·Efficacy
0.680.57–0.82
0.690.56–0.87
not pooledMajor deviation

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
Propensity-score weighting
Analysis method
Weighted Cox proportional hazards model
Missing data
Multiple imputation
DAG
Yes
QBA
Yes

Data and sample

Data type
EHR
Data sources
CPRD Aurum linked data
Geography
England
Eligible sample
62503
Treated
13239
Control
49264
Emulations
2
Treatments compared
2

Transparency

4/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Available from CPRD subject to approval
Code availability
https://github.com/dkdryan/empa_reg_tte
Conflicts of interest
Declared: Industry
COI institutions
Relationships listed on ICMJE disclosures
Funding
Declared: Public
Funders
National Institute for Health and Care Research

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Ryan_EMPAREG
DOI
10.1136/bmjdrc-2025-005672
Affiliations
University of Oxford and UK academic collaborators
Sector
Academia
Target trials (study level)
EMPA-REG OUTCOME
Registration
NCT01131676